Obesity Assessment
BMI ≥30 or ≥25 with comorbidities
All Pathways
Family MedicineManagement
Obesity Evaluation & Management (Endocrine Society 2022)
Obesity Evaluation & Management (Endocrine Society 2022): Obesity Assessment → Comprehensive Evaluation → BMI Stratification → Lifestyle Intervention (A...
Pathway Overview
12 steps
Algorithm Steps
12 total
01Start 02Action Comprehensive Evaluation
Identify contributing factors
- Medication review (obesogenic drugs)
- Screen for secondary causes: hypothyroidism, Cushing's
- Assess eating behaviors, food security
- Evaluate for sleep apnea
- Assess mental health (depression, binge eating)
03Decision BMI Stratification
Determine treatment intensity
- 25-29.9: Overweight
- 30-34.9: Class I Obesity
- 35-39.9: Class II Obesity
- ≥40: Class III Obesity
04Action Lifestyle Intervention (All)
Foundation of all obesity treatment
- Caloric deficit: 500-750 kcal/day reduction
- Physical activity: 150-300 min/week moderate
- Behavioral counseling
- Consider dietitian referral
- Goal: 5-10% weight loss initial target
05Decision Pharmacotherapy Eligible?
BMI ≥30 OR ≥27 with comorbidity
- Comorbidities: T2DM, HTN, dyslipidemia, OSA, NAFLD, PCOS
06Action Anti-Obesity Medications
FDA-approved options
- Semaglutide 2.4mg weekly (Wegovy): 15-17% WL
- Tirzepatide (Zepbound): 20-25% WL
- Phentermine-topiramate ER: 8-10% WL
- Bupropion-naltrexone: 5-6% WL
- Orlistat: 3-5% WL
07Action GLP-1 RA / GIP-GLP-1
Most effective agents
- Semaglutide: Start 0.25mg weekly, titrate to 2.4mg
- Tirzepatide: Start 2.5mg weekly, titrate to 15mg
- Titrate slowly (every 4 weeks) to minimize GI side effects
- Contraindicated: personal/family MTC, MEN2
08Decision 12-Week Response
Assess weight loss
- Response: ≥5% weight loss
- If <5% on max dose, consider alternative agent
09Action Continue Therapy
Long-term maintenance
- Medications often needed indefinitely
- Weight regain common if stopped
- Continue lifestyle modifications
- Monitor for side effects
10Decision Bariatric Surgery Eligible?
NIH criteria
- BMI ≥40
- BMI ≥35 with obesity-related comorbidity
- BMI ≥30 with T2DM (metabolic surgery)
- Failed lifestyle + pharmacotherapy
11Action Bariatric Surgery Referral
Most effective for severe obesity
- Sleeve gastrectomy most common
- Gastric bypass for DM, GERD
- 20-35% sustained weight loss
- Lifelong vitamin supplementation
- Multidisciplinary team required
- Path rejoins step 06Shared downstream outcome
- Path rejoins step 04Shared downstream outcome
12Action Address Comorbidities
Obesity-related conditions
- Screen for OSA (STOP-BANG)
- Assess and treat NAFLD
- Optimize glycemic control
- Manage hypertension, lipids
- Address mental health
Guideline Source
Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- GLP-1 RA availability and cost may limit access
- Bariatric surgery referral criteria simplified
- Does not address pediatric obesity
- Weight regain prevention not detailed
- Insurance coverage varies significantly
Contraindicated Populations
pregnancy
Applicable Regions
USAUUKEU
AU: NHMRC obesity guidelines
UK: NICE obesity pathway
US: Endocrine Society and AGA guidelines
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Obesity Evaluation & Management (Endocrine Society 2022)?
The Obesity Evaluation & Management (Endocrine Society 2022) is a management clinical algorithm for Family Medicine. It provides a structured decision tree to guide clinical decision-making, based on Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity.
What guideline is the Obesity Evaluation & Management (Endocrine Society 2022) based on?
This algorithm is based on Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity (DOI: 10.1210/clinem/dgab842).
What are the limitations of the Obesity Evaluation & Management (Endocrine Society 2022)?
Known limitations include: GLP-1 RA availability and cost may limit access; Bariatric surgery referral criteria simplified; Does not address pediatric obesity; Weight regain prevention not detailed; Insurance coverage varies significantly. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Obesity Evaluation & Management (Endocrine Society 2022) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free